Targets › SLC10A2
4 programs from 3 companies in 8 trials: 4 Phase 3, 3 Phase 2, 1 Phase 4; Gastroenterology, Other, Respiratory; next expected readout Jan 2027.
Plays a critical role in the sodium-dependent reabsorption of bile acids from the lumen of the small intestine. Transports various bile acids, unconjugated or conjugated, such as cholate and taurocholate. (UniProt, Q12908)
Open in Phaseline: the race on SLC10A2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Mirum Pharmaceuticals | Maralixibat Ileal bile acid transporter inhibitor | SLC10A2 | Phase 4 | Alagille Syndrome; Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC); Constipation Chronic Idiopathic | Feb 2027 |
| Albireo, an Ipsen Company | Odevixibat Ileal bile acid transporter inhibitor | SLC10A2 | Phase 3 | Biliary Atresia; Alagille Syndrome | Feb 2027 |
| GSK | Linerixibat Ileal bile acid transporter inhibitor | SLC10A2 | Phase 3 | Cholestasis | – |
| Mirum Pharmaceuticals | Volixibat Ileal bile acid transporter inhibitor | SLC10A2 | Phase 2 | Primary Biliary Cholangitis; Primary Sclerosing Cholangitis | Jan 2027 |
Alagille Syndrome (2) Cholestasis (1) Biliary Atresia (1) Primary Biliary Cholangitis (1) Primary Sclerosing Cholangitis (1) Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC) (1) Constipation Chronic Idiopathic (1)
small molecule (4)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.